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Detection of hepatitis B virus DNA and RNA in kidneys of HBV-related
glomerulonephritis. Glomerular deposition of hepatitis B virus (HBV)
antigens are observed in chronic HBsAg carriers with different glomeru-
loncphritides yet the etiologic role of HBV remains uncertain. We
examined the paraffin section of kidney biopsies from 40 chronic HB5Ag
carriers with membranous nephropathy (MGN), mesangiocapillary gb-
merulonephritis (MCGN) or IgA nephropathy (IgAN) for HBV DNA and
HBV RNA using in Situ hybridization (ISH). Glomerular HBV antigens
were present in all biopsies by immunofluorescence. HBsAg or HBcAg
mRNA was also studied in RNA extracted from frozen renal tissue using
a two-step polymerase chain reaction (PCR) following reverse transcrip-
tion (RT). HBcAg DNA was not easily detected with ISH alone, but was
readily found in 31 biopsies (78%) following PCR. HBV DNA was
detected mainly in the cytoplasm of proximal tubular epithelia but not in
glomerular cells. HBsAg and/or HBcAg mRNA were detected by RT-
PCR in extracted RNA from 13 biopsies (33%). The PCR findings were
further confirmed by (a) Southern blot hybridization using a cloned HBV
probe and (b) absence of PCR product following treating RNA with
RNase or omitting the RT. It is plausible that HBV DNA in renal tubules
represents endocytosis of HBV DNA in the urinary filtrate and the HBV
RNA extracted from kidney biopsies could derive from infiltrating cells
bearing HBV RNA. Hence, ISH with specific HBV core gene RNA probe
was performed subsequently. HBcAg RNA, localized in the nuclei and
cytoplasm of glomerular and tubular cells, was detected in 56%, 20%, and
36% of renal biopsies in chronic HBsAg carriers with MGN, MCGN, and
IgAN, respectively. Our findings indicate the presence of viral transcrip-
tion in glomerular cells and renal tubular epithelia, supporting an etio-
logical role of HBV in some chronic HBsAg carriers who develop
coexisting glomerulonephritides.
The association between chronic hepatitis B virus (HBV)
infection, characterized by persistent hepatitis B surface antigen-
emia, and renal disease was first reported in 1971 [1]. Among the
various morphologic patterns of HBV-related glomerulonephrit-
ides, membranous nephropathy (MGN) is the best recognized
disorder [2, 3]. The hepatitis B e antigen (HBeAg) has been
suggested to exert an important pathogenetic role in chronic HBV
carriers who have coexisting membranous nephropathy [4, 5].
Mesangial proliferative gbomerulonephritis (MPGN) with mesan-
gial IgA and hepatitis B surface antigen (HBsAg) deposits and
mesangiocapillary glomerulonephritis (MCGN) have also been
reported mainly in adult population raising a possible etiological
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association between HBV and IgA nephropathy or MCGN in
some chronic HBsAg carriers [3, 6—8].
The pathogenetic mechanism of HBV in these HBV-related
glomerulonephritides remains unclear. HBV-related membra-
nous nephropathy (HBV-MGN) is suggested as a circulating
immune complexes (CICs) mediated disease due to glomerular
trapping of CICs [9, 10], despite the fact that CICs containing
HBV antigens have been demonstrated in some but not all
patients with HBV-MGN [11—13]. The pathogenesis of HBV-
related IgA nephropathy (HBV-IgAN) and HBV-related mesan-
giocapillary glomerulonephritis (HBV-MCGN) most likely in-
volves mesangial and subendothelial trapping of CICs, and
observations that infusion of preformed CICs primarily results in
mesangial and subendothelial deposits will support this mecha-
nism [14].
Nevertheless, animal model of membranous nephropathy de-
termining the structural and functional expression of subepithelial
immune deposit formation supports the concept of immune
complex (IC) formation in situ in primary membranous nephrop-
athy [15]. Numerous studies of the fate of infused preformed
immune complexes have generally failed to reveal subepithelial
localization [161 and the viral replication of 1-IBV in kidneys of
these patients has been debated. Glomerular detection of HBV
viral DNA has been reported in kidneys of chronic HBsAg
carriers with different glomerulonephritides [17—19] yet the con-
sistency of these findings remains controversial, since other inves-
tigators have been unable to detect similar findings in chronic
HBV carriers with coexisting membranous nephropathy [20]. This
issue is of interest in the understanding of the pathogenesis of
HBV-related glomerubonephritides. Therefore, we have taken
advantage of the sensitivity and specificity of the molecular
biology techniques to search for HBV DNA or RNA sequences in
the kidney tissues of patients with HBV-related glomerulone-
phritides.
Methods
Patients
We studied 40 consecutive patients of Southern Chinese origin
with a diagnosis of HBV-related glomerulonephritides between
1988 and 1992. In all patients, the diagnosis was established by
percutaneous kidney biopsy and the pathology revealed membra-
nous nephropathy 14, mesangiocapillary glomerulonephritis 8,
and IgA nephropathy (mesangial proliferative glomerulonephritis
with predominant IgA deposits) 18. The criteria for patient
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selection followed those defined previously (18, 21]. These in-
cluded: no history of jaundice or liver disease; no history of blood
transfusion; no history of intravenous drug use; no clinical or
laboratory evidence of systemic disease known to cause membra-
nous nephropathy; seronegative for hepatitis C virus infection by
ELISA (Anti-HCV EIA; Abbott Laboratories, Abbott Park, IL,
USA); hepatitis B surface antigenemia on repeated testing;
proteinuria (> 0.5 g per day); and evidence of HBV antigen(s) in
glomeruli. Twelve patients (30%) had mild elevation of serum
alanine aminotransferase on routine tests but none had liver
biopsies.
Seroloic tests for HBV
Tests for HBV antigens and antibodies were performed two
months before and at the time of renal biopsy and regularly
thereafter. Hepatitis B surface antigen (HBsAg) was measured by
enzyme immunoassay (Auszyme monoclonal; Abbott). Anti-HBs
antibody, antibody to hepatitis B core antigen (HBcAg), HBeAg,
and anti-HBe antibody were measured by enzyme immunoassay
(Corzyme, Ausab, HBe enzyme immunoassay; Abbott). The HBV
DNA was detected in the sera (taken at the time of renal biopsy)
by a dot-spot hybridization technique as described previously [22]
and the lowest detection limit was 0.1 pg/mI. In the same serum
sample, the surface antigen and core antigen regions of HBV
RNA were detected by a two-step polymerase chain reaction
(PCR) modified from the techniques described by Wright et al
[23] and Cristiano et al [241.
Morphologic and immunopathologic studies
Renal specimens were processed for light microscopic exami-
nation, immunofluorescent studies, and electron microscopy by
standard methods [25]. Capillary deposition of HBeAg was de-
tected either by F(ab')2 fragments of murine monoclonal antibody
against HBeAg or polyclonal antibody against HBcAg as previ-
ously reported [21, 25, 34]. Specificity of these antibodies had
been verified in previous studies [21, 25, 34]. Renal tissues were
also frozen rapidly and stored at —70°C until for extraction of
total RNA.
In-situ polymerase chain reaction hybridization for HBV DNA
Preparation of tissue sections and pretreatment. Paraffin sections
(4 jim) were cut and placed onto organosilane-coated glass slides
[26] and dried at 50°C overnight. The sections were dewaxed twice
in xylene for 15 minutes, absolute alcohol for 10 minutes twice,
followed by rehydration through graded alcohols. The slides were
washed in Tris-buffered saline (TBS, 0.05 M Tris-HCI, 0.15 M
NaCI, pH 7.6) and then immersed in 20% acetic acid for 15
seconds at 4°C to destroy the endogenous tissue alkaline phos-
phatase [27]. After several wash in TBS, the sections were treated
with proteinase K (0.2 to 0.5 mg/mI) (Sigma Chemical Co., St.
Louis, MO, USA) at 42°C for 15 minutes, heated to 90°C for three
minutes followed by post-fixation in 4% paraformaldehyde for five
minutes. Finally, the slides were washed thoroughly in TBS and
air dried.
In situ polymerase chain reaction (PCR). The PCR mixture
containing 3 mrvi MgCI2, 1 X PCR buffer (50 m'vi KC1 and 10 mM
Tris-HCI, pH 8.3) (Cetus, Perkin Elmer, Norwalk, CT, USA), 0.2
mM each of dATP, dTTP, dGTP and dCTP, 1 jiM each of the 5'
and 3' inner primers (Table 1) was applied to the sections and
covered by plastic coverslips. The slides were then placed on a
Table 1. Primers used for detection of HBV RNA
Amplimer
length
Sequence° (base pairs)
Outer primers 5'-GTTAGGGTFFAAATGTATACCC-3' 416
(surface gene) 5 '-CATCTFCTTATTGGTFCTFCTGG-3'
Inner primers 5 '-CATCTFCTFATTGGTFCTFCTGG-3' 263
(surface gene) 5 '-AATGGCACTAGTAAACTGAGCC-3'
Outer primer 5'-ACTGTI1TCAAGCCTCCAAGCT-3' 425
(core gene) (1861-1880)
5'-AGTGCGAATCCACACTC-3'
(2286-2270)
Inner primer 5 '-AGTGCGAATCCACACTC-3' 399
(core gene) (1 861-1880)
5 '-GGGTGGCmGGGGCATGGA-3'
Derived from Wright and coworkers [231
65°C hot plate, and overlaid with pre-warmed mineral oil after the
addition of 4 units of AmpliTaq DNA polymerase (Cetus, Perkin
Elmer) per section. PCR was carried out on a hot plate (Omni-
Gene, Hybaid, Middlesex, UK) programmed as follows: 10 min-
utes delay at 82°C and three minutes denaturation at 94°C
followed by 30 cycles of 94°C for one minute, 54°C for two
minutes and 72°C for two minutes. After PCR, the coverslips were
removed by immersing the slides in xylene and absolute alcohol
for two minutes each, post-fixed in 4% paraformaldehyde, washed
extensively in TBS and allowed to air dry.
In situ hybridization. In situ PCR products were detected by the
use of the HBV core gene fragment labeled with biotin-1 l-dUTP
(Sigma). A hybridization mixture containing 50% deionized for-
mamide, 5% dextran sulfate, 2 >< SSC and biotinylated HBV
probe (0.5 ng/jil) was added to the sections, covered by plastic
coverslips and overlaid with mineral oil. After denaturation at
95°C for eight minutes on a hot plate, the slides were hybridized
at 42°C overnight in a moist chamber.
Detection of in situ PCR products. After hybridization, plastic
coverslips were removed and the sections were immersed in TBS.
Hybridization signals were detected using the In Situ Hybridiza-
tion Detection System (Dako, Copenhagen, Denmark) with minor
modifications. Briefly, the slides were immersed in the pre-
warmed stringent wash solution (1.5 mM sodium citrate, 15 mM
NaCI, 2 mrvi MgCl2, 0.1% Triton X-100, 0.5 g/liter BSA and 0.3
m sodium azide) and were incubated at 42°C for 15 minutes
twice. Nonspecific streptavidine binding sites were blocked by
incubation with 2% BSA in 0.1 M Tris-HC1, pH 7.5, 0.1 M sodium
chloride and 0.05% triton X-100 for five minutes [27]. After a
brief wash in TBS, streptavidine-alkaline phosphatase reagent was
applied to each section for 20 minutes at room temperature. The
sections were washed in TBS for five minutes twice followed by
incubation with a 5-bromo-4-chloro-3-iridolyl phosphate/nitro-
blue tetra-zolium (BCIP/NBT) substrate solution (including 1 mist
Levamisole) in a dark at room temperature for 20 to 60 minutes.
Finally, the slides were bathed in TBS for five minutes, counter-
stained with nuclear fast red, dehydrated through graded alcohols
and mounted.
PCR testing of kidney tissue or serum for HBV RNA
Polymerase chain reaction. Total RNA was extracted from 1 to
5 mg of frozen kidney biopsy samples according to the guanidium
isothiocyanate—cesium chloride method [28, 29] or from 50 jil
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Table 2. Results of serologic testing in patients and controls
HBV DNA
pg/mi
HBsAg carriers with IgAN
1. AA F/19 + — + (65) — —
2. AB M/63 - + ND -
3. AC F/47 — + ND — —
4. AD F/SO + — ND — —
5. AE F/33 — + ND — —
6. AF M/18 — + ND not done not done
7. AG F/39 — — ND not done not done
8. AH M/43 - + ND - -
9. Al F/27 — + ND + —
10. A.J M/37 — — ND — —
11. AK M/38 + ND - -
12. AL M/44 — + ND — —
13. AM F/28 + + (137) — —
14. AN F/31 + — + (640) not done not done
15. AO M/30 — + + (256) + +
16. AP M/30 + + (213) — —
17. AQ F/24 + — + (426) — —
18. AR F/39 — + ND — —
HBsAg carriers with MCGN
19. BA F/39 — + ND not done not done
20. BB M/39 + — ND — —
21. BC F/44 — + ND — —
22. BD M/45 + — + (166) not done not done
23. BE M/58 — — + (17) — —
24. BF M/54 — + ND — +
25. BG M/32 + — + (736) — —
26. BH M/38 + — + (124) — —
HBsAg carriers with MGN
27. CA M/47 - + ND - —
28. CB M/24 + — ND — —
29. CC M/19 + — + (723) — +
30. CD M/53 + — + (448) — —
31. CE M/52 + — + (156) — —
32. CF F/39 — — ND — —
33. CG M/53 + - ND -
34. CH M/48 + — ND not done not done
35. CI M/38 + ND —
36. CJ M/42 + — + (48) — —
37. CK M/48 + ND - —
38. CL M/25 + — ND — —
39. CM M/9 + — + (211) — —
40. CN M/43 — + ND not done not done
HBsAg carriers with minimal change nephropathy
41. DA M/19 + ND
42. DB F/22 — — ND
43. DC M/35 — + ND
HBsAg carriers with focal glomerulosclerosis
44. EA M/46 + — + (65)
45. EB F/39 — + ND
46. EC M/29 — + ND
Non-HBsAg carriers with IgAN
47. FA M/32 — ND
48. FB M/28 — ND
49. FC F/22 — ND
Non-HBsAg carriers with MGN
50. GA M/45 - ND
51. GB F/30 — ND
52. GC F/28 — ND
Chronic HBsAg carriers with hepatitis
53. HA M/48 + + (784) + +
54. HB F/42 + + (12) +
Healthy non-HB5Ag carriers, died of traffic accident
55. IA M/28 — ND
56. lB M/39 — ND
Abbreviations are: HBV-SG, HBV surface mRNA; HBV-CG, HBV core mRNA; +, positive; —, negative; ND, not detected (the lowest detection
limit is 0.1 pg/mI).
Patient group
no/code Sexlage HBeAg Ariti-HBe HBV-SG HBV-CG
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samples of serum according to the acid guanidium thiocyanate-
phenol-chloroform extraction method [30, 31]. RNA was washed
with 70% ethanol, resuspended in diethylpyrocarbonate (DEPC)
treated H20 and stored at —70°C until use. The reverse transcrip-
tion was performed using a RT-PCR kit (Cetus, Perkin Elmer).
The reaction was carried out in a volume of 20 jil, which
contained 2.5 jiM Oligo d(T)16, 1 m of each of four deoxynucle-
otides, 10 m of Tris-HC1 (pH 8.3), 50 m of potassium chloride,
5 mM of magnesium chloride, and 50 U of cloned Moloney murine
leukemia virus reverse transcriptase, incubated at 42°C for 30
minutes. The complementary DNA (cDNA) product was ampli-
fied by a two-step PCR. The first round of DNA amplification was
done in a volume of 30 pA with 50 pmol of each outer primer to the
surface or core gene (Table 1), 3 jil of 10 X PCR buffer, 1 m of
each nucleotide triphosphate, and 2.5 U/100 jil of AmpliTaq
DNA polymerase (Cetus, Perkin Elmer) for 35 cycles (1 mm at
72°C, 1 mm at 95°C, 1 mm at 57°C) in a thermocycler (Cetus,
Perkin Elmer).
Ten microliters of the first round of PCR products was analyzed
by agarose gel electrophoresis and staining with ethidium bro-
mide, and 1 pA was used for a second round of amplification with
inner primers (either surface or core gene, 50 pmol each) (Table
1). To avoid contamination of samples, RNA extraction and
amplification of RNA were done in separate laboratory areas.
Positive (Orcein-stamning liver tumor from HBV carrier and
peripheral blood leukocytes from HBsAg carriers) and negative
controls (liver from non-HB5Ag carriers, kidney tissues from
three non-HBsAg carriers with primary membranous nephropa-
thy, three non-HBsAg carriers with IgA nephropathy, three
HBsAg carriers with coexisting minimal change nephropathy, and
three HBsAg carriers with focal glomerulosclerosis) were in-
cluded at the extraction step and both amplification steps.
Confirmation of HBV RNA. The specificity of HBV surface or
core antigen RNA was confirmed by Southern hybridization.
Hybridization probes were prepared by digestion with BamHI of
plasmid pAM6, a genomic clone of HBV [32]. After digestion, a
1.5 kilobase fragment containing the core antigen gene and a 1.7
kilobase fragment containing the surface antigen gene were
obtained [33]. The DNA fragments were then radioactively la-
beled with [32P]dCTP using Megaprime DNA labeling system
(Amersham, Aylesbury, UK). Unincorporated nucleotides were
removed by passing through a Sephadex G-50 spun column.
PCR products were electrophoresised in 1.2% agarose at 150 V
for 2.5 hours followed by vacuum blotting (LKB, Pharmacia,
Uppsala, Sweden). Briefly, DNA separated in gel was depurinated
with 0.2 N HC1 for 15 minutes. After a brief wash in distilled water,
the gel was immersed by denaturation solution (0.5 M NaOH, 0.5
M NaCI) for 15 minutes and neutralized with 1.5 M NaCI and 0.5
M Tris-HCI (pH 7.5) for 15 minutes. The DNA was then trans-
ferred to a nylon membrane (Hybond-N; Amersham) in 20 x SSC
(1 x SSC is 0.15 M NaCI plus 0.015 M sodium citrate) for one hour
followed by UV cross-linkage fixation.
Prehybridization was carried out in 6 X SSC, 0.5% SDS, 5X
Denhardt's solution with 100 jig/mI Salmon sperm DNA (Sigma)
at 65°C for four hours. 32P-labeled fragment was then added and
hybridization was completed at 65°C overnight. The filter was
washed twice in 2 X SSC, 0.1% SDS at 65°C and twice in 0.1 X
SSC, 0.1% SDS at 65°C for 15 minutes per wash. Autoradiography
was carried out at room temperature overnight.
Control of sensitivity and specificity. The present two-step PCR
testing has been shown to be highly sensitive in detecting HBV
DNA by other investigators [231. Serial dilution of known
amounts of HBV DNA showed that a single round of PCR
amplification was able to detect 15 virions/mI, and two rounds of
PCR amplification was able to detect 0.15 virions/ml. The two-
step PCR assay was capable of detecting 2700 molecules/mI viral
RNA [23]. Nevertheless, this high level of sensitivity may easily
lead to false positive results due to minute contaminations.
Therefore, the following precautions were taken to ensure the
validity of the results. (i) Precautions to avoid carryover of PCR
product included physical separation of pre-PCR and post-PCR
mixtures and aliquots of reagents, the use of positive displacement
pipettes, and the avoidance of aerosols. (ii) The results were
considered valid only if these were consistent in repeated (at least
twice) independent experiments. (iii) Contamination by plasmids
containing HBV insert was excluded. (iv) Negative controls
including kidney RNA samples from non-HBV carriers as well as
a reaction mixture without RNA or DNA were run in each
experiment. (vi) Hybridization was performed under stringent
conditions. (vii) Confirmation of HBV RNA was performed by
repeating the PCR without reverse transcription. (viii) Further
validation of HBV RNA was achieved by treating the extracted
RNA with DNase-free RNase [Sigma] prior to reverse transcrip-
tion and PCR.
In situ hybridization for HBV RNA
It is plausible that the presence of glomerular or tubular HBV
DNA results from either filtering by the glomerular basement
membrane or endocytosis by proximal tubular epithelia when the
HBV DNA in the urinary filtrate crosses their luminal borders.
Alternatively, the presence of HBV RNA in mRNA extracted
from kidney biopsies could derive from infiltrating polymorphs
and macrophages bearing HBV RNA. Hence, in situ hybridization
with HBV core gene RNA probe was performed in paraffin
sections.
Preparation of RNAprobe. HBV core gene fragments generated
from PCR of pAM6 [32] using inner primer set (Table 1) were
purified and cloned into PCR-Script SK(+) plasmid (Strat-
agene, La Jolla, CA, USA) using the Srfl site. Ligation was
performed overnight with T4 DNA ligase (Boehringer Mann-
heim, Germany) at room temperature and plasmids were trans-
formed into TGI. Colonies containing inserts were primary
screened by Southern blot hybridization and then by ScreenTest
Recombination Screening kit (Stratagene) as specified by the
manufacturer. Sequence of the selected clone was finally con-
firmed by DNA sequencing (Sequenase Version 2.0 DNA se-
quencing Kit, US Biochemical). Plasmids with cloned inserts were
served as templates for RNA probe preparation.
Digoxigenin-UTP labeled RNA probes (anti-sense) were syn-
thesized from the template by using the Dig RNA labeling kit
(SP6/T7) (Boehringer Mannheim). Briefly, 1 jig of template was
linearized by NotI restriction enzyme (Boehringer Mannheim)
and then transcribed by T7 RNA polymerase in the presence of
Dig-UTP. Transcription was carried out at 37°C for two hours.
The template DNA was removed by DNase treatment. Sense
probes were synthesized from the same template using T3 RNA
polymerase. Labeled RNA probes were precipitated with 4 M LiC1
and ethanol and were stored in DEPC-H20 with a ribonuclease
inhibitor at —20°C until use.
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Table 3. Results of in Situ hybridization in tissues from patients and controls
Patient
Results of renal tissue testing
HBV-DNA HBV-DNA HB5Ag mRNA HBcAg mRNA HBcAg RNA
group detected
no/code Sex/age by ISH
detected by
PCR + ISH
detected
by RT.PCR1'
detected
by RT-PCR'
detected
by ISH
HBsAg carriers with IgAN
1. AA Ff19 — +(T) — — —
2. AB M/63 — + (T) — — —
3. AC F/47 — + (T) — — —
4. AD Ff50 — — — —
5. AE F/33 — — — — ND
6. AF M/18 + (T) — — ND
7. AG F/39 — + (T) — — ND
8. AH M/43 — + (T) — — —
9. Al F/27 — — — — ND
10. AJ M/37 — — — — —
11. AK M/38 — — +(G,T)
12. AL M/44 — + (T) — — + (G,T)
13. AM F/28 — + (T) + + ND
14. AN Ff31 — + (T) + — ND
15. AD M/30 — + (T) — —
16. AP M/30 + (T) + + ND
17. AQ F/24 — +(T) — + +(G,T)
18. AR F/39 — — — — +(G,T)
HBsAg carriers with MCGN
19. BA F/39 — — — — ND
20. BB M/39 — + (T) — — —
21. BC F/44 — — — — ND
22. BD M/45 — + (T) + + —
23. BE M/58 — + (T) — —
24. BF M/54 — + (T) — ND
25. BG M/32 — — — — —
26. BH M/38 — + (T) + — + (G, T)
HB5Ag carriers with MGN
27. CA M/47 — — — — + (G, T)
28. CB M/24 — + (T) + + ND
29. CC M/19 (T) + + ND
30. CD M/53 — + (T) + — +(G,T)
31. CE M/52 — +(T) + + +(G,T)
32. CF F/39 — + (T) — + ND
33. CG M/53 + (T) + (T) — + —
34. CH M/48 — + (T) — — + (G, T)
35. CI M/38 — — — — —
36. Ci M/42 — — + (G, T)
37. CK M/48 + (T) + (T) — — + (G, T)
38. CL M/25 — — — ND
39. CM M/19 - — ND
40. CN M/43 + (T) — ND
HBsAg carriers with minimal change nephropathy
41. DA M/19 —
42. DB F/22 —
43. DC M/35
HBsAg carries with focal glomerulosclerosis
44. EA M/46 —
45. EB F/39 —
46. EC M/29 —
Non-HBsAg carriers with IgAN
47. FA M/32 —
48. FB M/28 —
49. FC F/22 —
Non-HB5Ag carriers with MGN
50. GA M/45 —
51. GB Ff30 —
52. GC Ff28 —
1970 Lai et al: HBV and chronic glomerulonephritis
Table 3. Continued
Results of liver tissue testing
Patient HBV-DNA HBV-DNA HB5Ag mRNA HBcAg mRNA HBcAg RNA
group detected
no/code Sex/age by 1ST-I"
detected by
PCR + ISW
detected
by RTPCRt
detected
by RT-PCR"
detected
by ISH"
Chronic HB5Ag carriers with hepatitis
53. HA M/48 + (N) + (N) + + + (N)
54. HB F/42 — + (N) + + + (N)
Healthy non-HB5Ag carriers, died of traffic accident
55. IA M/28 — — — — —
56. lB M/39 — — — — —
Abbreviations are: ISH, in situ hybridization; PCR, polymerase chain reaction; RT, reverse transcription; ND, not done due to insufficient tissue; G,
glomerular cells; T, tubular cell; N, nuclear; +, positive; —, negative; trace; N.B. HBV-DNA refers to HBcAg DNA.
a Paraffin section of the tissue
b Frozen tissue
RNA in situ hybridization (RISH). Slides for RISH were dew-
axed and rehydrated through graded ethanol to DEPC-H20.
After 10 minutes bath in 0.2 HC1, sections were digested with
proteinase K at 37°C for 10 minutes, followed by several washes in
DEPC-H20. All the sections were then treated with RQ1 RNase-
free DNase 1(1 U/LJ; Progema, Madison, WI, USA). For control
sections, RNase (RNase A, 2 mg/mI; Sigma) was applied in
addition. After one hour of incubation, slides were washed three
times in DEPC-H20 for five minutes each, dehydrated and air
dried.
A hybridization mix containing 50% deionized formamide, 2 X
SSC, 10% dextran sulfate, 50 .tg/ml tRNA (transfer RNA; Sigma)
and RNase inhibitor (RNasin Ribonuclease Inhibitor; Progema)
was added to each section and covered with plastic coverslips.
After denaturation at 62°C for five minutes, hybridization was
carried out at 42°C for two hours.
Hybridization signals were detected with the use of Dig Wash
and Block Buffer Set (Boehringer Mannheim). Briefly, slides were
washed for 30 minutes in wash solution (1.5 m sodium citrate, 15
mM NaCI, 2 mvt MgC12, 0.1% Triton X-100, 0.5 g/liter BSA and
0.3 m sodium azide) after hybridization. Nonspecific binding
sites were blocked by incubation in blocking buffer for 30 minutes.
Anti-digoxigenin-alkaline phosphatase (Boehringer Mannheim)
diluted in blocking buffer (1:500) was added to the sections for 30
minutes. The slides were then washed in TBS (0.05 M Tris-I-IC1,
0.15 M NaCl, p1-I 7.6) for five minutes twice and incubated in AP
substrate buffer (0.1 M Tris-HC1, pH 9.0, 0.05 M MgCl2, 0.02 M
NaCI) for five minutes. Signals were developed with substrate
solution (BCIP-NBT) for 15 minutes to overnight in the dark. The
slides were then counterstained with nuclear fast red, dehydrated
through graded ethanol, immersed in xylene and mounted.
Control of specificities for in situ hybridization. For the in situ
detection of HBV DNA and RNA, the following control experi-
ments were carried out in order to rule out the possibilities of
artifacts and nonspecific findings: (i) use of biotin-labeled plas-
mids (pBR322) as probes in negative control experiments, (ii) use
of digoxigenin-labeled probes in parallel with the biotin-labeled
probes, (iii) DNase digestion in all sections in RISH and (iv)
confirmation of RNA detected by running parallel experiments
with sense probes or with RNase digestion.
Statistics
For analysis of seropositivity for HBV DNA or presence of
HBV DNA in renal biopsies from HBsAg carriers with nephrop-
athy, the Fisher's exact test or Chi-square test was used as
appropriate. Statistical significance was determined to be P <
0.05.
Results
Patient demographics
The three groups of patients with HBV-related glomerulone-
phritis were comparable in age despite two of the HBsAg carriers
with MGN were younger than 10 years. Nevertheless, there was a
male predominance among HBsAg carriers with MGN or MCGN
as compared with those with IgAN (g2 test = 8.67, P < 0.02). All
these patients with HBV-related glomerulonephritis had a creat-
mine clearance >50 ml/min/1.73 m2, and none of the patients had
previously received any immunosuppressive therapy at the time of
the study.
Serologic findings
All of the 40 patients were seropositive for HB5Ag and had high
titers of anti-HBc antibody suggesting that they were chronic
HBV carriers (Table 2). HBeAg was detected in the sera of 11 of
14 patients with MON (79%), in 4 of the 8 patients with MCGN
(50%), and in only 5 of 18 patients with IgAN (28%). The
incidence of seropositivity for HBeAg amongst patients with
MGN was significantly higher than that of MCGN or IgAN (
test = 8.13, P < 0.002). HBV DNA was detected in the sera of 5
patients with MGN (36%), 4 patients with MCGN (50%), and 6
patients with IgAN (33%) (g test = 0.686, P = 0.710). HBcAg or
HB5Ag RNA was only detected in the sera of 1 patient with
MGN, 1 patient with MCGN, and 2 patients with IgAN. These
HBV serologic markers (including anti-HBe) were not detected in
the other groups of non-HBsAg carrier controls. The 6 HBV
carriers with coexisting minimal change nephropathy or focal
glomeruloscierosis were seropositive for HBsAg and anti-HBc
antibody, yet HBeAg, HBV DNA or HBV RNA was not detected
in their sera.
Pathologic findings
The renal biopsies of the 14 HBsAg carriers with MGN showed
uniform thickening of the glomerular basement membrane on
light microscopy with a "spike" pattern evidenced on silver
staining. Crescent formation and tubular atrophy were infrequent
pathologic findings. Immunofluorescence studies with the use of
monoclonal antibodies against HBeAg or polyclonal antibodies
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Fig. 1. (A) Renal biopsy specimen from a chronic HBsAg carrier with HBJ/-related MGN (case 31, CE). HBcAg DNA is not detected with in situ
hybridization alone (negative signals in nuclei and cytoplasm were counterstained as pink by Nuclear Fast Red) (streptavidine-alkaline phosphatase
stain, x380). (B) Renal biopsy specimen from the same patient. Diffuse cytoplasmic HBcAg DNA (purple color) is readily detected in proximal renal
tubular epithelia with PCR followed by in situ hybridization. HBcAg DNA is not detected in resident cell of the glomerulus (arrows) (X380). (C) Renal
biopsy specimen from a chronic HB5Ag carrier with HBV-related IgAN (case 17, AQ). HBcAg DNA is not detected with in situ hybridization alone
(X380). (D) Renal biopsy specimen from same patient. Diffuse cytoplasmic HBcAg DNA (deep purple color) is readily detected in proximal renal
tubular epithelia with PCR followed by in Situ hybridization. HBcAg DNA is not detected in resident cells of the glomerulus (arrows) (x450).
Publication of this figure in color was made possible by a grant from the Thomas and Rita Liu Research Fund, Hong Kong.
against HBcAg revealed granular deposits of HBeAg along the
glomerular capillary wall in a pattern similar to that of IgG,
though with a lower intensity. The HBV antigen in these speci-
mens studied by polyclonal antibody was highly likely to be
HBeAg since the polyclonal anti-HBc antiserum was shown to
contain both anti-HBc and anti-HBe activities [25]. The renal
biopsies of the 18 HBsAg carriers with IgAN showed focal or
diffuse mesangial proliferation with different degrees of sclerosis
and tubulointerstitial changes. Immunofluorescence studies re-
vealed predominant mesangial IgA deposits. Studies for HBV
antigens showed mesangial deposits of HBsAg similar to that of
IgA, again with a lower intensity. Pathologic examination of renal
biopsies from HBsAg carriers with MCGN revealed mesangial
expansion and splitting of basement membrane. Immunofluores-
cence studies demonstrated predominant granular IgG along the
basement membrane with mesangial IgG and/or IgA deposits. As
reported in previous studies [3, 8, 25, 34], HBeAg was deposited
along the capillary basement membrane while HBsAg was depos-
ited in the mesangial area. The use of F(ab')2 fragments of murine
monoclonal antibody excluded nonspecific staining or false-posi-
tive finding due to rheumatoid factor [5, 25, 35]. Glomerular HBV
antigens were detected in all biopsies, but HBV antigens were
rarely detected in renal tubules.
In situ polymerase chain reaction hybridization for HBV DNA
The paraffin sections of the tissue specimens were initially
studied for HBV DNA by in situ hybridization (Table 3). Liver
sections from chronic HBsAg carriers with chronic active hepatitis
were used as positive controls. Usually HBcAg DNA was easily
identified within the nucleus and cytoplasm of infected hepato-
cytes by in situ hybridization alone (case 53: HA). However, in
carriers with low HBsAg titer and low serum concentration of
1-IBV DNA (case 54: HB), HBcAg DNA was only demonstrable
with in situ hybridization following PCR. HBcAg DNA was not
A C
M I 2 3 4 5 6 7 8 9 10 M
ee:
M 1 2 3 4 5 6 7 8 9 10
— 416bp
— 263 bp
bp
1353
1078
872
603
310
281 271
116
72
B
416bp —
283bp —
bp
1!!
310
72
D
— 425 bp
— 399 bp
M 1 2 3 4 5 6 7 8 9 10M 1 2 3 4 5 6 7 8 9 10
0 S 425 bp —399 bp — eeeS
1972 Lai et aI: HBV and chronic glomerulonephritis
Fig. 2. (A) Detection of HBcAg mRNA in kidney biopsies from patients with HB V-related MGN by two-step (nested) RT-PCR. Lane (M) represents 4,X174
HaeIIl digested DNA. Lane 1 is a positive control from plasmid with HBV DNA sequence. The first PCR product is diluted tenfold and both outer
and inner HBcAg DNA sequences are detected. Lane 2 is a positive RNA isolated from Orcein-staining human liver tumor (case 53, HA). Lanes 3 and
4 are RNA from renal biopsies of non-HBsAg carriers with primary MGN (cases 50 GA 51 GB). Lanes 5 to 10 are RNA from 6 renal biopsies of
HBV-related MGN (case 28 CB to case 33 CG in consecutive order) and HBcAg gene is detected in cases 28, 29, 31, 32, and 33). (B) Confirmation
of HBcAg mRNA in kidney biopsies from patients with HBV-related MGN. The HBcAg mRNA is first amplified by nested RT-PCR. The eDNA is
confirmed by Southern blot hybridization using a fragment from the cloned HBV probe (ATCC 45020-pAm6). The lanes correspond to those described
in panel A. (C) Detection of HB5Ag mRNA in kidney biopsies from patients with HBV-related MGN by two-step (nested) RT-PCR. The first PCR
product is diluted tenfold and both outer and inner HB5Ag DNA sequences are detected. The lanes correspond to those described in panel A, and the
HB5Ag gene is detected in cases 28, 29, 30, and 31). (D) Confirmation of HB5Ag mRNA in kidney biopsies from patients with HBV-related MGN. The
HB5Ag mRNA is first amplified by nested RT-PCR. The eDNA is confirmed by Southern blot hybridization using a fragment from the cloned HBV
probe (ATCC 45020-pAm6). The lanes correspond to those described in panel A.
detected with in situ hybridization following PCR in renal biopsies
from non-HBsAg carriers with primary membranous nephropathy
(cases 50 to 52) or non-HBsAg carriers with primary IgA ne-
phropathy (cases 47 to 49). In renal biopsies from our chronic
HBsAg carriers with MGN, MCGN, or IgAN, HBcAg DNA was
frequently not detectable with in situ hybridization alone. Never-
theless, HBcAg DNA was readily detectable in most of these renal
tissues when PCR was performed prior to in situ hybridization.
HBcAg DNA was detected in 86%, 63%, and 77% of renal
biopsies in chronic HBsAg carriers with MGN, MCGN, and
IgAN, respectively (Table 3). Figure 1 B and D illustrate the
detection of HBcAg DNA by in situ hybridization following DNA
amplification with PCR in renal biopsy from a chronic HBsAg
carrier with MGN and a chronic HBsAg carrier with IgAN,
respectively. The HBcAg DNA was localized in the proximal renal
tubules but not in the glomerular cells despite the presence of
specific HBV antigen(s) in the mesangium or in the basement
membrane. The tubular localization was either diffuse or focal.
Contrary to the findings in hepatocytes, the localization of HBcAg
DNA in renal tubules was cytoplasmic, and very occasionally
equivocal staining of HBcAg DNA was detected in the nuclei. The
use of digoxigenin-labeled probes in parallel with the biotin-
labeled probes showed identical findings. The serologic detection
of HBV DNA did not correlate with the presence of HBV DNA
in renal tissue (P = 0.117, Fisher's exact test).
PCR testing of RNA extracted from kidney tissue for HBV Rh/A
PCR testing allowed us to identify HBsAg mRNA and/or
HBcAg mRNA sequences reproducibly in extracted RNA from
kidneys from 6 of the 14 chronic HBsAg carriers with MGN
(43%), from 2 of 8 chronic HBsAg with MCGN (25%), and from
5 of the 18 chronic HBsAg carriers with IgAN (28%) (A test =
A C
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Fig. 3. (A) Detection of HBcAg mRNA in kidney biopsies from patients with HBI/-related IgAN by two-step (nested) RT-PCR. Lane (M) represents 4X 174
HaeIII digested DNA. Lane 1 is a positive control from plasmid with HBV DNA sequence. The first PCR product is diluted tenfold and both outer
and inner HBcAg DNA sequences are detected. Lane 2 is a positive RNA isolated from Orcein-staining human liver tumor (case 53, HA). Lanes 3 and
4 are RNA from renal biopsies of non-HB5Ag carriers with primary IgAN (cases 47 FA and 48 FB). Lanes 5 to 20 are RNA from 16 renal biopsies of
HBV-related IgAN (case 2 AB to case 17 AQ in consecutive sequence) and HBcAg gene is detected in cases 14, 17, and 18). Lane 21 represents negative
control using ddH2O. (B) Confirmation of HBcAg mRNA in kidney biopsies from patients with HBV-related IgAN. The HBcAg mRNA is first
amplified by nested RT-PCR. The eDNA is confirmed by Southern blot hybridization using a fragment from the cloned HBV probe (ATCC
45020-pAm6). The lanes correspond to those described in panel A. (C) Detection of HB5Ag mRNA in kidney biopsies from patients with HBV-related
IgAN by two-step (nested) RT-PCR. The first PCR product is diluted tenfold and both outer and inner HBsAg DNA sequences are detected. The lanes
correspond to those described in panel A, and the HBsAg gene is detected in cases 14, 15, 16, and 17. (d) Confirmation of HBsAg mRNA in kidney
biopsies from patients with HBV-related IgAN. The HB5Ag mRNA is first amplified by nested RT-PCR. The eDNA is confirmed by Southern blot
hybridization using a fragment from the cloned HBV probe (ATCC 45020-pAm6). The lanes correspond to those described in panel A.
1.07, P = 0.585; Table 3). Both HBsAg and HBcAg mRNA were
identified in positive controls of Orcein-staining liver tumor from
chronic HBV carriers and kidney tissues from some chronic
HBsAg carriers with MGN or IgAN (Figs. 2 A, C, and 3 A, C).
Similar findings were not found in kidneys from chronic HBsAg
carriers with coexisting minimal change nephropathy (MCN) or
focal glomeruloscierosis (FGS), or non-HBsAg carriers with
MGN or IgAN, The specificity of HBsAg or HBcAg mRNA was
confirmed by Southern hybridization using specific hybridization
probes (Figs. 2 B, D and 3 B, D). Further confirmation and
validation of HBsAg or HBcAg mRNA was achieved by absence
of PCR products detected either by agarose gel or by Southern
hybridization when the PCR was performed without reverse
transcription or when RT-PCR was performed in extracted RNA
pretreated with DNase-free RNase (Fig. 4). All mRNA samples
that were positive for HBsAg or HBcAg mRNA showed negative
findings following PCR when RT was not performed or the
extracted RNA was pretreated with RNase.
In situ hybridization for HBV RNA
Subsequently, in situ hybridization with HBV core gene RNA
probe was performed in paraffin sections (Table 3). A 399-bp PCR
generated fragment was prepared by amplification of sequences
corresponding to the core gene position (1861 to 2285) of HBV
genome [23] with the inner primer set (Table 1). Direct sequenc-
ing result revealed that the fragment was inserted into the Srfl site
of PCR-Script SK( +) plasmid with bacteriophage T7 promotor
attached.
Liver sections from chronic HBsAg carriers with hepatoma
were used as positive controls. HBcAg RNA was easily identified
within the nucleus and cytoplasm of infected hepatocytes (Fig.
5A). Signals were absent if the sections were pretreated with
RNase (Fig. SB) or when the in situ hybridization was performed
with sense probe. Sufficient sections were only available from 25
biopsies (MGN 9, MCGN 5, and IgAN 11) for in situ hybridization
studies of HBcAg RNA. HBcAg RNA was detected in 56%, 20%,
and 36% of renal biopsies in chronic HBsAg carriers with MGN,
MCGN, and IgAN, respectively ( test = 1.80, P = 0.406).
HBcAg RNA was readily detectable in glomerular cells and
proximal renal epithelia (Fig. 6 A, C). HBcAg RNA was clearly
detected in nuclei and was diffusely present in the cytoplasm.
Glomerular HBcAg RNA was localized in mesangial and epithe-
hal cells in biopsies from chronic HBsAg carriers with IgAN (Fig.
6A). In chronic HBsAg carriers with MGN, glomerular HBcAg
RNA was present mainly in epithelial cells (Fig. 6C). Signals were
absent if the sections were pretreated with RNase (Fig. 6 B, D).
A
__ A II B I C __
bp
1353 —
107 —
87 —
603
310 =
194 —
118 —
72 —
B
M12345
__ A__
MI 23 45
M12345 Ml 2345
MI 2 34 SM 12 345
*
e
I B ____ C
1974 Lai et a1: HBV and chronic glomerulonephritis
Fig. 4. illustration that PCR product is derived from RNA but not from DNA. (A) Lane (M) represents 4X174 HaeIII digested DNA. Lanes I and 2
represent RT-PCR product with HB5Ag gene primers and HBcAg gene primers respectively. Lane 3 represents RT-PCR product with RNA pretreated
with RNase before RT-PCR with HBsAg gene primers. Lane 4 represents RT-PCR product with RNA pretreated with RNase before RT-PCR with
HBcAg gene primers. Lane 5 represents PCR product with PCR reaction using both HBsAg gene and HBcAg gene primers but omitting the RT. Group
A represents plasmid DNA with HBV DNA sequence. Group B and Group C represent RNA from case 13 AM and case 28 CB, respectively. The
plasmid DNA with HBV DNA sequence is not affected by RNase or by omitting PCR. Nevertheless, PCR product with RNA from patients with
HBV-related IgAN or MGN is not formed when RNA is pretreated with RNase or the RT is omitted. All mRNA samples that are positive for HB5Ag
or HBcAg mRNA show negative findings following PCR when RT is not performed or the extracted RNA is pretreated with RNase. (b) The eDNA
is confirmed by Southern blot hybridization using the corresponding fragment from the cloned HBV probe (ATCC 45O20-pAm6).
The serologic detection of HBV DNA did not correlate with
presence of HBcAg RNA in renal tissue (P = 0.468, Fisher's exact
test). HBcAg RNA was not detected in renal biopsies from
non-HBsAg carriers with primary membranous nephropathy (cas-
es 50 to 52) or non-HBsAg carriers with primary IgA nephropathy
(cases 47 to 49). In renal biopsies from our 6 HBsAg carriers with
MCN or FGS, glomerular IC containing HBV antigens were
absent. Neither HBV RNA nor HBV DNA was found in glomer-
ular or tubular cells.
Discussion
The pathogenetic role of I-IBV in different glomerulonephriti-
des is not well defined. A recent study in woodchuck with chronic
woodchuck hepatitis virus infection revealed renal pathologies
similar to those of human described in this study [36]. Wood-
chucks with MGN appeared to be younger whereas those with
MPGN (with mesangial IgA deposits) were older, and there was
a male predominance amongst affected animals compared with
the chronic carriers. The only difference from human disease is
that the woodchuck HBeAg system has not been characterized.
The pathogenetic mechanism in these HBV-related glomerulo-
nephritides remains unclear. Local formation of antigen and
antibody complexes has been well established to induce the diffuse
subepithelial immune deposits and proteinuria characteristic of
HBV-MGN [151. Similarly, the demonstration by in situ hybrid-
ization of HBV DNA within the glomeruli in patients with
HBV-MGN [19] and the identification of both free and integrated
HBV DNA in kidneys of chronic HBsAg carriers, including a
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Fig. 5. (A) Liver biopsy specimen from control patient (case 53, HA)
showing hepatocytes with detectable nuclear (deep purple color) (arrows) and
cytoplasmic HBcAg RNA (light brownish blue color) with in situ hybridiza-
tion (anti-digoxigenin-alkaline phosphatase stain; X600). (B) HBcAg RNA
is not detected in the same liver biopsy specimen by in situ hybridization
if the specimen was pretreated with RNase (negative signals in nuclei were
counterstained as pink by Nuclear Fast Red) (X450). Publication of this
figure in color was made possible by a grant from the Thomas and Rita Liu
Research Fund, Hong Kong.
Fig. 6. (A) Renal biopsy specimen from a chronic HBsAg carrier with
HBI/-related MGN (case 31, CE). Nuclear and cytoplasmic HBcAg RNA
(purple color) is detected with in situ hybridization in glomerular (small
arrows) and tubular cells (large arrows) (X600). (B) HBcAg RNA is not
detected in the same kidney biopsy specimen by in situ hybridization if the
specimen was pretreated with RNase (negative signals in nuclei were
counterstained as pink by Nuclear Fast Red; ><450). (C) Renal biopsy
specimen from a chronic HBsAg carrier with HBV-related IgAN (case 17,
AQ). Nuclear and cytoplasmic HBcAg RNA (deep purple color) is
detected with in situ hybridization in glomerular (small arrows) and
tubular cells (large arrows) (anti-digoxigenin-alkaline phosphatase stain;
X600). (D) HBcAg RNA is not detected in the same kidney biopsy
specimen by in situ hybridization if the specimen was pretreated with
RNase (negative signals in nuclei and cytoplasm were counterstained as
pink by Nuclear Fast Red; X450). Publication of this figure in color was
made possible by a grant from the Thomas and Rita Liu Research Fund,
Hong Kong.
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patient with HBV-MGN, may favor the notion that HBV may also
infect resident glomerular cells leading to immune complexes
formation in situ [16].
This study demonstrates, by means of a highly sensitive proce-
dure (PCR and in situ hybridization), the frequent presence of
HBV DNA within the cytoplasm of the renal proximal tubules in
patients with different entities of HBV-related glomerulonephrit-
ides. The HBV DNA might not be detected with in situ hybrid-
ization alone yet could readily be demonstrated following ampli-
fication with PCR. Nevertheless, HBV DNA was not detected in
the glomerular cells. Lin [19] detected HBV DNA in glomeruli
and tubular epithelia by in situ hybridization in children with
recent-onset HBV-MGN (all seropositive for HBV DNA), but it
is most intriguing that the HBV DNA in glomerulus was exclu-
sively located extracellularly. The HBV DNA disappeared in all
glomeruli and renal tubules from patients with no disease pro-
gression six months after onset. A study of Pekin duck infected
with duck HBV revealed only cytoplasmic localization of HBcAg,
as observed in our patients, in the tubular epithelia of the kidney
[37]. The presence of HBcAg or HBV DNA in the tubular
epithelia could indicate HBV replication in the tubular epithelia,
and these findings are in keeping with other transgenic mice
studies revealing the expression of viral genome of HBcAg or
HBeAg only in tubular epithelia [38, 39]. Our documentation of
HBV transcriptionally active genomes, using a highly sensitive
two-step PCR, further supports the notion that HBV replicates in
renal tissues of infected animals. Overall, 44% of the renal
biopsies were positive for HBV RNA by RISH using paraffin
block sections. This percentage is higher than the 33% detected by
RT-PCR using RNA extracted from frozen tissues. The discrep-
ancy is due to the degradation of RNA with prolonged storage.
The frozen tissues were kept at —70°C for 2.5 to 6.5 years before
extraction for RNA and RNA degradation was expected to occur
with prolonged storage. On the other hand, paraffin fixation of
renal tissues is likely to provide a better preservation of HBV
RNA. Hence, the incidence of HBV RNA detection by RISH in
paraffin sections is higher than that with RT-PCR in frozen tissues
despite the latter technique is more sensitive. Similarly, a higher
incidence of detection of HBV DNA is observed in paraffin
sections used for PCR hybridization when compared with HBV
RNA detection in frozen tissues by RT-PCR.
It is plausible that the presence of glomerular or tubular HBV
DNA results from either filtering by the glomerular basement
membrane or endocytosis by proximal tubular epithelia when the
HBV DNA in the urinary filtrate crosses their luminal borders.
Alternatively, the presence of HBV RNA in mRNA extracted
from kidney biopsies could derive from infiltrating polymorphs
and macrophages bearing HBV RNA. Hence, in situ hybridization
with specific HBV core gene RNA probe was performed subse-
quently. HBcAg RNA was localized in the nuclei and cytoplasm of
glomerular and tubular cells from biopsies from HBV-related
glomerulonephritides. The discrepancy in detecting HBcAg RNA
by in situ hybridization and by RT-PCR in extracted RNA is likely
to be due to RNA degradation in stored frozen tissue and in
paraffin section. The absence of signal in tissues from non-HBsAg
carriers and the stringent control of specificities for in situ
hybridization confirm the presence of HBV transcripts in glomer-
ular and tubular cells. Our findings support a pathogenetic
mechanism of in situ formation of immune complexes with
"planting" of HBV antigens in the glomeruli, but do not exclude
a contributory role of CIC in glomerular immune complex
deposition.
It remains perplexing why certain chronic HBsAg carriers
develop MGN whereas others develop IgAN or MCGN. This
could well be related to the HBV antigen status as well as the size
and charge properties of HBV antigens and their antibodies. It is
obvious from many studies that chronic HBsAg carriers with
MGN or MCGN have a high seropositive rate of HBeAg [3, 4, 6,
19, 21] whereas chronic HBsAg carriers with IgAN have a lower
seropositive rate of HBeAg [18, 35]. Extrapolating from the
experimental data of Germuth, Senterfit and Dreesman [40] and
Gallo et al [41], the smaller size of HBeAg [42] and the cationic
nature of anti-HBe of IgG isotype [43, 44] tend to attract the
subepithelial localization of HBeAg-anti-HBe complexes in HBV-
MN. In contrast, the larger size of HBsAg [45] and anionic nature
of IgA [46] favor the mesangial localization of HBsAg-anti-HBs
complexes in HBV-IgAN. HBV-MCGN is characterized by sub-
epithelial deposits of HBeAg and mesangial deposits of HBeAg.
In conclusion, our findings indicate that the host tissue tropism
of HBV is not limited to hepatocytes, and active viral transcription
is present in glomerular cells and renal tubular epithelia. Hepatitis
B virus is the etiologic agent in some chronic HBsAg carriers with
coexisting membranous nephropathy, mesangiocapillary glomer-
ulonephritis, or IgA nephropathy.
Acknowledgments
This study was supported by the Research Grant Committee (Hong
Kong) grant number 221400290 and the Rita and Thomas Liu Research
Fund (Hong Kong). Reproduction of the Figures 1, 5 and 6 in color was
made possible by a grant from the Thomas and Rita Liu Research Fund
(Hong Kong).
Reprint requests to Professor Kar Neng La4 Department of Medicine,
Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin,
Hong Kong.
Appendix
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circulating immune complexes, CICs.
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